APOA1 and cardiovascular disorder: Thus, apoA-I has emerged as a viable therapeutic participant at the crossroads between cardiovascular disease and cancer, considering the growing evidence of biological and mechanistic overlap between these two main causes of mortality worldwide [79–81].